Explore

Trendline Trendline
Vir Biotechnology Reports Strong Financial Position and Advances in Cancer and Hepatitis Delta Programs

Vir Biotechnology Reports Strong Financial Position and Advances in Cancer and Hepatitis Delta Programs

Vir Biotechnology Reports Strong Financial Position and Advances in Cancer and Hepatitis Delta Programs
Trendline Trendline
Contineum Therapeutics Reports Q1 2026 Financial Results and Clinical Milestones

Contineum Therapeutics Reports Q1 2026 Financial Results and Clinical Milestones

Contineum Therapeutics Reports Q1 2026 Financial Results and Clinical Milestones
Trendline Trendline
BioNTech Reduces COVID-19 Vaccine Production, Resulting in Job Cuts

BioNTech Reduces COVID-19 Vaccine Production, Resulting in Job Cuts

BioNTech Reduces COVID-19 Vaccine Production, Resulting in Job Cuts
Trendline Trendline
Zai Lab Reports Q1 2026 Financial Results and Advances Oncology Pipeline

Zai Lab Reports Q1 2026 Financial Results and Advances Oncology Pipeline

Zai Lab Reports Q1 2026 Financial Results and Advances Oncology Pipeline
Trendline Trendline
Generate Biomedicines Reports Q1 2026 Financial Results Amid Clinical Advancements

Generate Biomedicines Reports Q1 2026 Financial Results Amid Clinical Advancements

Generate Biomedicines Reports Q1 2026 Financial Results Amid Clinical Advancements
Trendline Trendline
Nuvectis Pharma Reports Increased Net Loss in Q1 2026 Amid Clinical Expansion

Nuvectis Pharma Reports Increased Net Loss in Q1 2026 Amid Clinical Expansion

Nuvectis Pharma Reports Increased Net Loss in Q1 2026 Amid Clinical Expansion
Trendline Trendline
Nuvectis Pharma Reports Increased Net Loss in Q1 2026

Nuvectis Pharma Reports Increased Net Loss in Q1 2026

Nuvectis Pharma Reports Increased Net Loss in Q1 2026
Trendline Trendline
Allarity Therapeutics Advances Stenoparib Manufacturing for Phase 3 Trials in Ovarian Cancer

Allarity Therapeutics Advances Stenoparib Manufacturing for Phase 3 Trials in Ovarian Cancer

Allarity Therapeutics Advances Stenoparib Manufacturing for Phase 3 Trials in Ovarian Cancer
Trendline Trendline
Odyssey Therapeutics Sets Terms for $225 Million IPO Amid Resurgent Biotech Market

Odyssey Therapeutics Sets Terms for $225 Million IPO Amid Resurgent Biotech Market

Odyssey Therapeutics Sets Terms for $225 Million IPO Amid Resurgent Biotech Market
Trendline Trendline
NImmune Biopharma Presents Promising Data for IBD Treatment at Digestive Disease Week

NImmune Biopharma Presents Promising Data for IBD Treatment at Digestive Disease Week

NImmune Biopharma Presents Promising Data for IBD Treatment at Digestive Disease Week
Trendline Trendline
IDEAYA Biosciences Reports Positive Results and Business Updates for Q1 2026

IDEAYA Biosciences Reports Positive Results and Business Updates for Q1 2026

IDEAYA Biosciences Reports Positive Results and Business Updates for Q1 2026
Trendline Trendline
Summit Shares Plummet as Cancer Drug Fails Early Survival Benchmark

Summit Shares Plummet as Cancer Drug Fails Early Survival Benchmark

Summit Shares Plummet as Cancer Drug Fails Early Survival Benchmark